The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Hospital Finances Split Into Haves and Have-Nots

A widening gap is emerging across US hospital finances, according to Becker's Hospital Review. The strongest systems are adding services, shedding what does not fit, and posting gains. Weaker hospitals are losing money, cutting costs, and in some cases running on fumes.

The divide is visible in cases like Watsonville (Calif.) Community Hospital, which Becker's reports is down to minimal reserves. The forces behind the split are familiar but intensifying: scale advantages for large systems, unfavorable payer mix at struggling facilities, persistent labor and supply costs, and uneven access to capital. Hospitals with strong balance sheets can invest in growth and weather disruption. Those without face service cuts, closures, or acquisition.

In practice, this means geography increasingly determines care access. Rural and safety-net hospitals sit on the vulnerable side of the line, while well-capitalized systems consolidate their advantage. The result is a consolidating market where financial strength compounds, and the gap between winners and losers keeps growing.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.